Chordate Medical Holding AB (publ) (CMH.ST)
SEK 12.6
(-1.18%)
SEK 12.6
(-1.18%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -29.57 Million SEK | -5.73% |
| 2022 | -28.02 Million SEK | -28.9% |
| 2021 | -21.74 Million SEK | -11.95% |
| 2020 | -19.42 Million SEK | 20.87% |
| 2019 | -24.54 Million SEK | 7.81% |
| 2018 | -26.62 Million SEK | -15.07% |
| 2017 | -23.13 Million SEK | -44.93% |
| 2016 | -15.96 Million SEK | 4.42% |
| 2015 | -16.7 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -6.01 Million SEK | 39.89% |
| 2024 Q2 | -7.13 Million SEK | -18.59% |
| 2023 Q4 | -10 Million SEK | -96.22% |
| 2023 Q1 | -7.11 Million SEK | 15.95% |
| 2023 Q3 | -5.1 Million SEK | 30.64% |
| 2023 Q2 | -7.35 Million SEK | -3.41% |
| 2023 FY | -29.63 Million SEK | -5.73% |
| 2022 Q1 | -7.38 Million SEK | -3.08% |
| 2022 FY | -28.02 Million SEK | -28.9% |
| 2022 Q4 | -8.46 Million SEK | -37.01% |
| 2022 Q3 | -6.17 Million SEK | -2.9% |
| 2022 Q2 | -6 Million SEK | 18.78% |
| 2021 FY | -21.74 Million SEK | -11.95% |
| 2021 Q1 | -5.79 Million SEK | -3.8% |
| 2021 Q2 | -5.05 Million SEK | 12.8% |
| 2021 Q3 | -3.71 Million SEK | 26.44% |
| 2021 Q4 | -7.16 Million SEK | -92.7% |
| 2020 Q1 | -5.42 Million SEK | 10.07% |
| 2020 Q4 | -5.58 Million SEK | -38.04% |
| 2020 FY | -19.42 Million SEK | 20.87% |
| 2020 Q3 | -4.04 Million SEK | 7.16% |
| 2020 Q2 | -4.35 Million SEK | 19.73% |
| 2019 FY | -24.54 Million SEK | 7.81% |
| 2019 Q1 | -6.17 Million SEK | 9.98% |
| 2019 Q2 | -5.99 Million SEK | 2.88% |
| 2019 Q3 | -6.33 Million SEK | -5.76% |
| 2019 Q4 | -6.03 Million SEK | 4.76% |
| 2018 Q3 | -6.17 Million SEK | 4.08% |
| 2018 FY | -26.62 Million SEK | -15.07% |
| 2018 Q2 | -6.43 Million SEK | 4.46% |
| 2018 Q1 | -6.74 Million SEK | 8.96% |
| 2018 Q4 | -6.85 Million SEK | -11.0% |
| 2017 Q1 | -4.29 Million SEK | -56.4% |
| 2017 FY | -23.13 Million SEK | -44.93% |
| 2017 Q2 | -5.44 Million SEK | -27.02% |
| 2017 Q3 | -5.99 Million SEK | -10.02% |
| 2017 Q4 | -7.4 Million SEK | -23.48% |
| 2016 Q3 | -3.89 Million SEK | 19.15% |
| 2016 Q2 | -4.81 Million SEK | 0.0% |
| 2016 FY | -15.96 Million SEK | 4.42% |
| 2016 Q4 | -2.74 Million SEK | 29.59% |
| 2015 FY | -16.7 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.55 Million SEK | 61.869% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 109.838% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 109.838% |
| Arcoma AB | 4.66 Million SEK | 734.583% |
| Bactiguard Holding AB (publ) | -131.93 Million SEK | 77.586% |
| BICO Group AB (publ) | -618.3 Million SEK | 95.217% |
| Boule Diagnostics AB (publ) | 39.27 Million SEK | 175.303% |
| CellaVision AB (publ) | 167.05 Million SEK | 117.702% |
| Clinical Laserthermia Systems AB (publ) | -65.93 Million SEK | 55.149% |
| C-Rad AB (publ) | 44.24 Million SEK | 166.837% |
| Duearity AB (publ) | -25.76 Million SEK | -14.783% |
| Dignitana AB (publ) | -15.02 Million SEK | -96.803% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 68.806% |
| Getinge AB (publ) | 3.81 Billion SEK | 100.775% |
| Scandinavian Real Heart AB (Publ) | -68.44 Million SEK | 56.796% |
| Iconovo AB (publ) | -45.77 Million SEK | 35.4% |
| Integrum AB (publ) | 6.51 Million SEK | 554.085% |
| Luxbright AB (publ) | -25.8 Million SEK | -14.599% |
| Mentice AB (publ) | -679 Thousand SEK | -4255.165% |
| OssDsign AB (publ) | -91.95 Million SEK | 67.842% |
| Paxman AB (publ) | 12.61 Million SEK | 334.342% |
| Promimic AB (publ) | -9.11 Million SEK | -224.321% |
| Qlife Holding AB (publ) | -168.69 Million SEK | 82.471% |
| SciBase Holding AB (publ) | -53.93 Million SEK | 45.176% |
| ScandiDos AB (publ) | -13.48 Million SEK | -119.325% |
| Sectra AB (publ) | 518.49 Million SEK | 105.703% |
| Sedana Medical AB (publ) | -65.54 Million SEK | 54.885% |
| Senzime AB (publ) | -133.74 Million SEK | 77.89% |
| SpectraCure AB (publ) | -21.35 Million SEK | -38.502% |
| Stille AB | 44.95 Million SEK | 165.785% |
| Vitrolife AB (publ) | -3.58 Billion SEK | 99.176% |
| Xvivo Perfusion AB (publ) | 38.5 Million SEK | 176.797% |